Cabergoline

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

Safety and Potency of a High Cabergoline Dosage in Microprolactinomas

A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

Cabergoline in Metastatic Breast Cancer

Satisfaction of Patients With the Chosen Method of Inhibition of Lactation

Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions

Cabergoline in Nonfunctioning Pituitary Adenomas

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol